Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292637 | 1.00 | CA1 (0.39) | CA1CA2CASRMEN1KMT2A | |
| SCHEMBL5026917 | 0.86 | CHRM3 (0.33) | CA1CA2CASRMEN1KMT2A | |
| SCHEMBL2048837 | 0.82 | CTSK (0.36) | CA1CA2CASRMEN1KMT2A | |
| SCHEMBL16994594 | 0.82 | CASR (0.37) | CA1CA2CASRKMT2AALDH1A1 | |
| SCHEMBL8717149 | 0.79 | CA1 (0.53) | CA1CA2CASRMEN1KMT2A | |
| SCHEMBL4284255 | 0.78 | — | — | |
| SCHEMBL4288962 | 0.78 | CASR (0.36) | CA1CA2CASRMEN1KMT2A | |
| SCHEMBL2032726 | 0.78 | CASR (0.36) | CA1CA2CASRMEN1KMT2A | |
| SCHEMBL4284462 | 0.76 | CA1 (0.51) | CA1CA2CASRMEN1KMT2A | |
| SCHEMBL6047160 | 0.75 | MEN1 (0.39) | CASRMEN1KMT2ACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102937-B2 | Stable and selective formation of hoogsteen-type triplexes and duplexes using twisted intercalating nucleic acids (TINA) and process for the preparation of TINA | TINA HOLDING APS (DK) | 2015-08-11 | — | — | US | disclosed |
| EP-1888748-B1 | STABLE AND SELECTIVE FORMATION OF HOOGSTEEN-TYPE TRIPLEXES AND DUPLEXES USING TWISTED INTERCALATING NUCLEIC ACIDS (TINA) AND PROCESS FOR THE PREPARATION OF TINA | TINA HOLDING APS (DK) | 2013-08-28 | — | — | EP | disclosed |
| US-20090216003-A1 | STABLE AND SELECTIVE FORMATION OF HOOGSTEEN-TYPE TRIPLEXES AND DUPLEXES USING TWISTED INTERCALATING NUCLEIC ACIDS (TINA) AND PROCESS FOR THE PREPARATION OF TINA | TINA HOLDING APS (DK) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216003-A1 | STABLE AND SELECTIVE FORMATION OF HOOGSTEEN-TYPE TRIPLEXES AND DUPLEXES USING TWISTED INTERCALATING NUCLEIC ACIDS (TINA) AND PROCESS FOR THE PREPARATION OF TINA | PCNA, DNA2, NUDT1 | CA1 3431/4885CA2 2764/4885CASR 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.